The predictive and prognostic value of TILs as a continuous variable in HER2-positive BC in the neoadjuvant setting was demonstrated in another analysis (n = 498) that evaluated TILs from two trials (GeparQuattro and GeparQuinto)108. This evidence concerns the gene ERBB2 and breast cancer.